5.44
price down icon3.37%   -0.19
after-market After Hours: 5.56 0.12 +2.21%
loading
Alpha Cognition Inc stock is traded at $5.44, with a volume of 6,361. It is down -3.37% in the last 24 hours and down -9.78% over the past month. Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
See More
Previous Close:
$5.63
Open:
$5.54
24h Volume:
6,361
Relative Volume:
0.07
Market Cap:
$87.15M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-1.9223
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
+2.45%
1M Performance:
-9.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$5.4279
$5.79
1-Week Range:
Value
$5.23
$5.79
52-Week Range:
Value
$4.66
$7.00

Alpha Cognition Inc Stock (ACOG) Company Profile

Name
Name
Alpha Cognition Inc
Name
Phone
(858) 344-4375
Name
Address
1200-750 W PENDER ST, VANCOUVER
Name
Employee
5
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ACOG's Discussions on Twitter

Compare ACOG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACOG
Alpha Cognition Inc
5.44 87.15M 0 -14.72M -7.41M -2.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
504.77 129.62B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
666.87 72.91B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
604.96 36.76B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.76 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.19 27.86B 3.32B -860.46M -1.04B -8.32

Alpha Cognition Inc Stock (ACOG) Latest News

pulisher
Mar 10, 2025

Acetylcholinesterase Inhibitors Market is expected to reach - openPR

Mar 10, 2025
pulisher
Mar 05, 2025

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey

Mar 05, 2025
pulisher
Feb 27, 2025

Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia

Feb 27, 2025
pulisher
Feb 27, 2025

Alpha Cognition sets new executive and director compensation - Investing.com India

Feb 27, 2025
pulisher
Feb 20, 2025

Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Institutions profited after Alpha Cognition Inc.'s (NASDAQ:ACOG) market cap rose US$12m last week but retail investors profited the most - Simply Wall St

Feb 20, 2025
pulisher
Feb 12, 2025

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease - Business Wire

Feb 12, 2025
pulisher
Feb 07, 2025

Acetylcholinesterase Inhibitors Market Size, Share, Industry - openPR

Feb 07, 2025
pulisher
Jan 30, 2025

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile

Jan 30, 2025
pulisher
Jan 30, 2025

Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - citybuzz -

Jan 30, 2025
pulisher
Jan 22, 2025

OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times

Jan 22, 2025
pulisher
Jan 22, 2025

OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.

Jan 22, 2025
pulisher
Jan 22, 2025

Alpha Cognition to delist from Canadian Securities Exchange - MSN

Jan 22, 2025
pulisher
Jan 21, 2025

Acetylcholinesterase Inhibitors Market: Industry Growth - openPR

Jan 21, 2025
pulisher
Jan 18, 2025

Moves at FDA, NIH - BioCentury

Jan 18, 2025
pulisher
Jan 15, 2025

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace

Jan 15, 2025
pulisher
Jan 14, 2025

Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health

Jan 14, 2025
pulisher
Jan 14, 2025

Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan

Jan 14, 2025
pulisher
Jan 13, 2025

Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St

Jan 13, 2025
pulisher
Jan 09, 2025

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights

Jan 09, 2025
pulisher
Jan 09, 2025

China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - JCN Newswire

Jan 09, 2025
pulisher
Jan 08, 2025

Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL

Jan 08, 2025
pulisher
Jan 08, 2025

China Medical System (00867)Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks

Jan 08, 2025
pulisher
Jan 08, 2025

Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan

Jan 08, 2025
pulisher
Jan 08, 2025

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Business Wire

Jan 08, 2025
pulisher
Jan 07, 2025

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace

Jan 07, 2025
pulisher
Jan 03, 2025

Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews

Jan 03, 2025
pulisher
Jan 01, 2025

Alpha Cognition files to sell 1.45M common shares for holders - MSN

Jan 01, 2025
pulisher
Dec 20, 2024

Alpha Cognition announces private sale of equity securities - Investing.com

Dec 20, 2024
pulisher
Dec 16, 2024

Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks

Dec 16, 2024
pulisher
Dec 16, 2024

Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks

Dec 16, 2024
pulisher
Dec 16, 2024

CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile

Dec 16, 2024
pulisher
Dec 16, 2024

Alpha Cognition Announces Partial Exercise of Over-allotment Option - Business Wire

Dec 16, 2024
pulisher
Dec 12, 2024

Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail

Dec 12, 2024
pulisher
Dec 12, 2024

Alpha Cognition sees promising data for military-related trauma treatment - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail

Dec 12, 2024
pulisher
Dec 12, 2024

Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing

Dec 12, 2024
pulisher
Dec 11, 2024

Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com

Dec 11, 2024
pulisher
Dec 11, 2024

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace

Dec 11, 2024
pulisher
Dec 11, 2024

About Us - Financial Content

Dec 11, 2024
pulisher
Nov 20, 2024

Opening Day: Invizyne Technologies jumps after IPO - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com

Nov 20, 2024
pulisher
Nov 18, 2024

Alpha Cognition announces equity offering and warrant adjustments - Investing.com

Nov 18, 2024
pulisher
Nov 16, 2024

Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India

Nov 16, 2024

Alpha Cognition Inc Stock (ACOG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$307.24
price up icon 0.61%
$76.55
price up icon 1.97%
$32.77
price up icon 0.28%
$20.79
price up icon 8.34%
$99.47
price up icon 2.06%
biotechnology ONC
$259.19
price up icon 1.81%
Cap:     |  Volume (24h):